Kidney Disease: Understanding CKD Before It's Too Late

Your kidneys do extraordinary work around the clock. Each day, they filter roughly 200 liters of blood, remove waste and excess fluid, regulate blood pressure, balance electrolytes, and produce hormones that help make red blood cells and keep bones healthy. They do all of this quietly and efficiently — which is part of what makes kidney disease so treacherous. By the time most people notice something is wrong, the damage is already significant.

Chronic kidney disease — CKD — is the slow, progressive loss of kidney function over months or years. It is one of the most common chronic conditions in the United States, one of the leading causes of death, and one of the most undertreated diseases in medicine. The reason? In its early and middle stages, CKD produces no symptoms at all.

"More than 37 million Americans have chronic kidney disease. As many as 9 in 10 adults with CKD are not aware they have it — often until the disease is very advanced." — CDC, Chronic Kidney Disease in the United States, March 2026

KIDNEY DISEASE IN AMERICA (2026) • 37 million Americans with CKD — about 1 in 7 adults • 9 in 10 adults with CKD don't know they have it • 808,000 Americans with end-stage renal disease (ESKD) • #9 leading cause of death in the United States

WHAT IS CHRONIC KIDNEY DISEASE?

Chronic kidney disease is defined as kidney damage or reduced kidney function lasting three months or longer. The damage is usually irreversible — once kidney tissue is lost, it does not regenerate. CKD is classified by two measures: eGFR (estimated glomerular filtration rate), which reflects how well the kidneys filter blood, and albuminuria, the presence of protein in the urine — an early marker of kidney damage.

CKD is staged from G1 to G5 based on eGFR: • Stage G1: eGFR ≥90 — Normal or high (damage present; function normal) • Stage G2: eGFR 60–89 — Mildly reduced (monitor; control risk factors) • Stage G3a: eGFR 45–59 — Mild to moderately reduced (nephrology referral considered) • Stage G3b: eGFR 30–44 — Moderately to severely reduced (nephrology referral recommended) • Stage G4: eGFR 15–29 — Severely reduced (prepare for kidney replacement) • Stage G5: eGFR <15 — Kidney failure / ESKD (dialysis or transplant required)

CAUSES AND RISK FACTORS

CKD has many possible causes, but two conditions account for the overwhelming majority of cases in the U.S. — diabetes and high blood pressure — responsible for over 70% of all new kidney failure cases each year.

Diabetes (leading cause): High blood glucose damages the filtering units inside the kidneys over time. About 38% of adults with diabetes have CKD. Diabetic nephropathy is the single most common cause of kidney failure in the U.S.

High blood pressure (leading cause): Hypertension damages kidney blood vessels, reducing filtration capacity. About 1 in 5 people with high blood pressure has CKD — and CKD in turn worsens hypertension, creating a destructive cycle.

Glomerulonephritis: Inflammation of the kidney's filtering units, often autoimmune in origin (IgA nephropathy, lupus nephritis). The third leading cause of kidney failure.

Polycystic kidney disease: The most common genetic cause of kidney failure. ADPKD causes progressive cyst growth replacing healthy kidney tissue.

Nephrotoxic medications: Long-term NSAIDs (ibuprofen, naproxen), certain antibiotics, contrast dyes, and some chemotherapy agents can damage the kidneys.

Heart disease: "Cardiorenal syndrome" — where each organ's dysfunction accelerates the other — is a major driver of CKD progression and mortality.

CKD AND HEALTH EQUITY: Non-Hispanic Black adults are more than 4 times more likely to develop end-stage renal disease than non-Hispanic White adults. Hispanic adults have twice the rate of ESKD — a gap that has been growing, per the CDC's March 2026 report.

SYMPTOMS OF KIDNEY DISEASE

CKD is frequently called a "silent disease" because early-stage damage produces no noticeable symptoms. By the time symptoms appear — typically in stages G3b through G5 — significant kidney function has already been lost.

Early to mid-stage (often none): • Foamy or bubbly urine (protein) • Swelling in feet and ankles • Frequent urination at night • Fatigue or low energy • Persistent high blood pressure • Mild back or flank discomfort

Advanced / kidney failure: • Severe fatigue and weakness • Nausea, vomiting, appetite loss • Confusion or mental fog • Decreased urine output • Shortness of breath (fluid) • Itching and dry skin (uremia) • Muscle cramps, restless legs • Metallic taste in the mouth

Foamy urine and persistent leg or ankle swelling are among the earliest visible signs of kidney trouble. If you notice either — especially alongside diabetes or high blood pressure — ask your doctor for both an eGFR blood test and a urine albumin-to-creatinine ratio (uACR).

TESTING AND DIAGNOSIS

CKD can only be detected through blood and urine testing. The KDIGO 2024 Clinical Practice Guidelines and CDC both recommend testing for anyone with risk factors including diabetes, high blood pressure, heart disease, obesity, family history of kidney disease, or age over 60.

1. eGFR blood test: Estimated glomerular filtration rate, calculated from serum creatinine, reflects kidney filtration capacity. An eGFR below 60 for three or more months indicates CKD. The 2024 KDIGO guideline now incorporates cystatin C for more precise estimates in certain populations.

2. Urine albumin-to-creatinine ratio (uACR): Detects protein leakage in urine — a marker of kidney damage that can appear before eGFR declines. Essential for early detection and monitoring treatment response.

3. Kidney imaging: Ultrasound is standard first-line imaging to assess kidney size, structure, and blood flow. CT or MRI may be ordered for specific causes such as obstruction, cysts, or tumors.

4. Kidney biopsy: Recommended when the cause of CKD is unclear — particularly if glomerulonephritis or another specific kidney disease is suspected.

SLOWING PROGRESSION — THE TREATMENT LANDSCAPE IN 2026

There is no cure for CKD, and lost kidney function cannot be restored. But treatment has advanced significantly, particularly with SGLT2 inhibitors now a cornerstone of kidney-protective therapy.

2024–2026 Guideline Update — SGLT2 Inhibitors: SGLT2 inhibitors — empagliflozin, dapagliflozin, canagliflozin — are now standard of care for CKD patients with proteinuria, regardless of whether they have diabetes. The 2024 KDIGO guideline and 2026 KDIGO-ADA update both recommend SGLT2i to slow GFR decline, reduce albuminuria, lower cardiovascular risk, and prevent heart failure hospitalizations. This is the most significant advance in kidney-protective pharmacotherapy in two decades.

Blood pressure control (target below 130/80 mm Hg): Rigorous blood pressure control is the single most important modifiable factor in slowing CKD progression. ACE inhibitors and ARBs are preferred — they lower blood pressure and reduce protein leakage.

SGLT2 inhibitors: Landmark trials (CREDENCE, DAPA-CKD, EMPA-KIDNEY) demonstrated SGLT2i significantly reduce kidney failure risk, cardiovascular events, and mortality in CKD patients.

GLP-1 receptor agonists: For patients with diabetes, GLP-1 receptor agonists (semaglutide, liraglutide) now have emerging evidence for direct kidney-protective effects.

Finerenone: A new mineralocorticoid receptor antagonist approved for type 2 diabetes with CKD and albuminuria. Reduces kidney inflammation and fibrosis.

Diet and lifestyle: A kidney-friendly diet limits sodium, phosphorus, potassium (in later stages), and protein (0.8 g/kg/day for Stages G3–G5). Avoiding NSAIDs and nephrotoxic substances is critical.

Kidney replacement therapy (Stage G5): When kidney function fails (eGFR below 15), options include hemodialysis, peritoneal dialysis, and kidney transplantation. Transplantation offers the best long-term survival and quality of life for eligible patients.

COMPLICATIONS OF UNTREATED OR ADVANCED CKD

Cardiovascular disease: People with CKD are far more likely to die from a heart attack or stroke than from kidney failure itself.

Anemia: Damaged kidneys produce less erythropoietin, leading to fatigue, shortness of breath, and reduced exercise tolerance.

Mineral and bone disease: CKD disrupts calcium, phosphorus, and vitamin D metabolism, weakening bones and increasing fracture risk.

Hyperkalemia and electrolyte imbalances: Elevated potassium is a life-threatening complication of advanced CKD that can cause dangerous heart arrhythmias.

Uremic encephalopathy: Severe waste product buildup can cause confusion, seizures, and coma — a medical emergency signaling imminent kidney failure.

CKD is treatable — and progression can be substantially slowed. With the right combination of blood pressure control, SGLT2 inhibitors, diabetes management, and lifestyle modification, many people with CKD maintain stable kidney function for years or even decades. The key is catching it early and acting before damage accumulates.

GET TESTED — PROTECT YOUR KIDNEYS NOW

If you have diabetes, high blood pressure, heart disease, obesity, or a family history of kidney disease, ask your doctor for a kidney function panel at your next visit — a simple blood and urine test. If you've already been diagnosed with CKD, make sure you're seeing a nephrologist and receiving the latest kidney-protective therapies including SGLT2 inhibitors.

Sources: CDC — Chronic Kidney Disease in the United States (March 2026); NIDDK — Kidney Disease Statistics; National Kidney Foundation; KDIGO 2024 CKD Clinical Practice Guideline; KDIGO 2026 Diabetes and CKD Guideline Update; ADA Standards of Care in Diabetes 2026 — Section 11.